California Biopharmaceutical Firm's Treatment Results in 21.7% Weight Reduction

Buzzline

Shares of Viking Therapeutics, a biotechnology company based in California, soared by 40% on September 22 following the release of new findings indicating that its experimental weight loss medication, VK2735, enabled patients to shed an average of 21.7% of their body mass over a 33-week weekly treatment regimen. Patients who transitioned to biweekly dosing maintained up to 97% of their lost weight, while those on a monthly schedule retained as much as 90% during the subsequent 12 weeks. Analysts from Oppenheimer suggest that the drug's advantage may lie in its dosing flexibility rather than solely in weight reduction, as the obesity treatment market, currently dominated by Novo Nordisk and Eli Lilly, is anticipated to grow to $100 billion by the year 2030. Disclosure: This video contains stock footage and content created or enhanced using AI-assisted tools.  ai-generated

Transcript

00:00A California drugmaker's new weight loss shot just delivered results strong enough to send

00:04its stock soaring 40% in a single day. Viking Therapeutics says its experimental obesity drug,

00:12VK2735, helped patients lose an average of 21.7% of their body weight after 33 weeks of weekly

00:19treatment. Patients who then switched to dosing every other week kept up to 97% of the weight

00:25they had lost. While those on monthly maintenance doses held on to up to 90% over the following 12

00:31weeks, Oppenheimer analysts say the drug's real advantage may not be the weight loss number itself,

00:37but its flexibility and convenience for patients that matters because the obesity drug market,

00:42dominated by Novo Nordisk and Eli Lilly, is projected to reach $100 billion in sales by 2030.

00:49And Viking is now a serious new competitor. Disclosure. This video contains stock footage

00:54and content created or enhanced using AI-assisted tools.

Category

Transcript

Recommended